Deferoxamine mesylate

CAS : 138-14-7

Ref. 3D-D-0675

Informations sur le produit

• Nom: Deferoxamine mesylate
• Synonymes: Deforoxamine B mesylate, Ba 33112, Butanediamide, N⁴-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N¹-(5-aminopentyl)-N¹-hydroxy-, methanesulfonate (1:1), Butanediamide, N′-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy-, monomethanesulfonate (salt), DFX mesylate, Deferoxamine B mesylate, Deferoxamine Mesilate, Deferoxamine methanesulfonate, Deferrioxamine B methanesulfonate, Deferrioxamine methanesulfonate, Desferal, Desferal mesylate, Desferrioxamine B mesylate, Desferrioxamine B methanesulfonate, Desferrioxamine mesilate, Desferrioxamine mesylate, Desferrioxamine methanesulfonate, N'-{5-[acetyl(hydroxy)amino]pentyl}-N-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-hydroxybutanediamide methanesulfonate (1:1), N'-{5-[acetyl(hydroxy)amino]pentyl}-N-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-hydroxybutanediamide methanesulfonate (1:2), NSC 644468, Propionohydroxamic acid, N-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]-, methanesulfonate, Propionohydroxamic acid, N-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]-, monomethanesulfonate (salt), Butanediamide, N4-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N1-(5-aminopentyl)-N1-hydroxy-, methanesulfonate (1:1)

Description

Deferoxamine is a very well known drug for the treatment of iron excess occurring in patients with thalassemia who are receiving regular transfusions. Excessive iron intake from diet may also cause accumulation of the metal ions which result in several symptoms such as metabolic acidosis and hypovolemic shock. The mechanism of action of Deferoxamine is based on its ability to chelate iron and other metal ions (i.e. aluminum) permitting their rapid urinary elimination. Recently, another potential therapeutic uses of Deferoxamine for treating diabetic neuropathy was suggested since it was observed that the drug could activate the production of pro-angiogenic, neuroprotective and anti inflammatory factors. Read the full story here: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0178011

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 656.79 g/mol
• Formule: C₂₆H₅₂N₆O₁₁S
• Degré de pureté: Min. 98.0 Area-%